Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 791 to 800 of 1090 total matches.
Gleevec (STI-571) For Chronic Myeloid Leukemia
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001 (Issue 1106)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.
Aliskiren/Valsartan (Valturna) for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009 (Issue 1326)
(category D).
DRUG INTERACTIONS — The new combination
should be used cautiously with other drugs ...
The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment of hypertension in patients already taking both drugs or not adequately controlled on monotherapy, and as initial therapy in those likely to need multiple drugs to control their blood pressure.
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017 (Issue 1533)
and its metabolite can be found
in breast milk.
DRUG INTERACTIONS — Lesinurad is metabolized
by CYP2C9 ...
The FDA has approved Duzallo (Ironwood), a fixed-dose
combination of the uric acid transporter 1
(URAT1) inhibitor lesinurad (Zurampic) and the
xanthine oxidase inhibitor allopurinol (Zyloprim, and
generics), for once-daily treatment of gout-associated
hyperuricemia in patients who have not achieved
target serum uric acid levels with allopurinol alone.
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available ...
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available in the
US that delays the onset of type 1 diabetes.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):7-8 doi:10.58347/tml.2023.1667c | Show Introduction Hide Introduction
Buprenorphine: An alternative to Methadone
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003 (Issue 1150)
is contraindicated.
DRUG INTERACTIONS — Potent 3A4 inhibitors such as ketoconazole (Nizoral, and others ...
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only for parenteral use in treatment of pain (Buprenex, and others), it offers an alternative to methadone (Dolophine, and others), which is now often abused (New York Times, February 9, 2003; page 1). As a schedule III narcotic, buprenorphine will be subject to fewer prescribing restrictions than a schedule II drug such as methadone (MJ Kreek and FJ Vocci, J Subst Abuse Treat 2002;...
A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington
ADVISORY BOARD ...
The FDA has approved an oral, fixed-dose combination (Treximet - GlaxoSmithKline) of the selective serotonin receptor agonist ("triptan") sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium (Anaprox, and others) for acute treatment of migraine attacks.
A Granisetron Patch (Sancuso)
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008 (Issue 1301)
of Medicine
DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D.,
St. John’s University
PRODUCTION ...
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation (Sancuso - ProStrakan).
Artemether-Lumefantrine (Coartem) for Treatment of Malaria
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009 (Issue 1321)
, but some
experts would not prescribe it in the first trimester of
pregnancy.
7
DRUG INTERACTIONS — Use ...
The FDA has approved artemether-lumefantrine (Coartem - Novartis) for oral treatment of uncomplicated Plasmodium falciparum malaria. It is not approved for prophylaxis. Artemether-lumefantrine is the first artemisinin-based drug approved for use in the US. Artemisinins are Chinese herbal products used worldwide to treat malaria. The intravenous formulation of artesunate, another artemisinin, is available in the US through the CDC.
Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
.
DRUG INTERACTIONS — Rifaximin is a substrate of
P-glycoprotein (P-gp). Concomitant administration ...
Rifaximin (Xifaxan – Salix), a minimally absorbed
oral antibiotic approved previously to treat travelers'
diarrhea and to reduce the risk of recurrent hepatic
encephalopathy, has now been approved by the FDA
for treatment of irritable bowel syndrome with diarrhea
(IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid
receptor agonist, was also recently approved for IBS-D
and will be reviewed in a future issue.
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
with epilepsy.
DRUG INTERACTIONS — Patients should avoid concomitant
use of metoclopramide and antipsychotics ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.